Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva Pharmaceuticals (NYSE: TEVA ) stock is climbing higher on Thursday after the pharmaceutical company announced a new growth strategy. Teva Pharmaceuticals has laid out the four pillars of how it plans to grow with its new plan.

Why Is Teva Pharmaceuticals (TEVA) Stock Up Today?

Teva Pharmaceutical Industries' drug Austedo should reach sales of $2.5 billion by 2027, chief executive Richard Francis said on Thursday.

Teva Pharm CEO sees $2.5 billion in revenue for Austedo drug by 2027

Teva Pharmaceutical Industries on Thursday launched a new “pivot to growth” strategy, based on existing growth drivers like Austedo and Ajovy as well as generics, further innovation, and focused capital allocation. The company expects annual sales of more than $2.5 billion by 2027 for Austedo, which treats involuntary movements associated with Huntington's disease.

Teva Pharmaceutical announces new growth strategy built on biosimilars, innovation

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a new strategic framework with four main pillars to position the Company for a new era of growth. This strategy aims to bolster the Company's strong commercial portfolio with AUSTEDO®, AJOVY®, UZEDYTM and biosimilars, amplify its innovative pipeline, sustain its generics powerhouse and focus the business. These four pillars are expected to deliver enhanced value and create a greater imp.

Teva Launches New “Pivot to Growth” Strategy

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that once-daily AUSTEDO XR (deutetrabenazine) extended-release tablets are now available for adults in the United States in 6 mg, 12 mg and 24 mg tablet strengths. AUSTEDO XR was recently approved by the U.S. Food and Drug Administration (FDA) for adults living with tardive dyskinesia (TD) and chorea associated with Huntington.

AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.

TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.

TEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q1 2023 Earnings Conference Call May 10, 2023 8:00 AM ET Company Participants Ran Meir - SVP, Investor Relations Richard Francis - President & CEO Eli Kalif - CFO Eric Hughes - Chief Medical Officer, Head of Research and Development Sven Dethlefs - Head, North America Commercial Conference Call Participants Hassan Aftab - Bank of America Merrill Lynch Umer Raffat - Evercore ISI Balaji Prasad - Barclays Ash Verma - UBS Nathan Rich - Goldman Sachs Chris Schott - JPMorgan David Amsellem - Piper Sandler Operator Hello, and welcome to the Q1 2023 Teva Pharmaceutical Industries Limited earnings conference call. My name is Alex.

Teva Pharmaceutical Industries Limited (TEVA) Q1 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Teva Pharmaceutical Industries Ltd. (TEVA) Q1 Earnings: A Look at Key Metrics

Teva Pharmaceutical reported lighter-than-expected earnings for the first quarter, leading Teva stock to plunge early Wednesday. The post Teva Pharma Crumbles After First-Quarter Earnings Miss, Flat Sales appeared first on Investor's Business Daily.

Teva Pharma Crumbles After First-Quarter Earnings Miss, Flat Sales

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2023. Revenues of $3.7 billion GAAP loss per share of $0.18 Non-GAAP diluted EPS of $0.40 Cash flow used in operating activities of $145 million Free cash flow of $41 million Non-GAAP gross profit margin of 49.1% was mainly impacted by an unfavorable portfolio mix and an increase in COGS due to inflationary pressure. We expect our gross profit margi.

Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2022 Environmental, Social and Governance (ESG) Progress Report, which highlights the Company's achievements, such as completing more than 40% of its 23 long-term targets, including six ahead of schedule. The Company successfully met its 2030 target to increase energy efficiency, exceeded its 2030 target to reduce total water withdrawal in areas projected to be in water stress and me.

Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule

MONTPELLIER, France--(BUSINESS WIRE)--An original presentation describing pharmacokinetic characteristics of an investigational long-acting subcutaneous formulation of olanzapine (mdc-TJK or TEV-44749) will be communicated by MedinCell's partner Teva Pharmaceuticals at the 2023 Schizophrenia Investigational Research Society (SIRS) later this month. Data to be presented comes from a 127-participant phase 1 clinical study evaluating, among other things, the pharmacokinetics of single ascending do.

MedinCell: mdc-TJK's (Teva's codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada)

SANTA BARBARA, Calif. & PARSIPPANY, N.J.--(BUSINESS WIRE)--Direct Relief, the National Association of Free and Charitable Clinics (NAFC), and Teva Pharmaceuticals, U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced an expansion of medicine donations through their collaborative mental health access program into seven new states to advance access to healthcare for uninsured patients seeking treatment for anxiety and depression. Through “Community Routes:.

U.S. Mental Health Access Program Expands Medicine Donation to Seven New States

PARSIPPANY, N.J. & TEL AVIV & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced today that the U.S. Food and Drug Administration (FDA) has approved UZEDY (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. UZEDY is the first subcutaneous, long-acting formulation of risperidone that utilizes SteadyTeq™, a copolymer technology propriet.

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host an Investor Day on Thursday, May 18, 2023 to launch its new growth strategy and portfolio priorities. The event will take place at the New York Stock Exchange in New York City. Presentations will begin at 12:00 p.m. Eastern Time and are expected to conclude at 2:00 p.m. Eastern Time. Richard Francis, Teva's President and CEO, will detail a strategic framework and key pr.

Teva to Launch New Growth Strategy at Investor Day

Teva Pharmaceutical Is Stabilizing Hinting A Payoff Potential.

Teva Pharmaceutical Is Stabilizing Hinting A Payoff Potential

Catalyst Pharmaceuticals

Catalyst Pharma And Teva's ANDA Challenge: Firdapse Hangs By A Thread

Viatris

In theory, the stock of companies that make generic drugs have the potential to be safe investments. Despite that, companies like Teva Pharmaceuticals aren't actually safe at all.

1 "Safe" Stock to Avoid and 1 to Consider Buying in April

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2023 financial results on Wednesday, May 10, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.

Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced six poster abstracts across its neurology portfolio will be presented at the American Academy of Neurology (AAN) Annual Meeting on April 22-27, 2023. Abstracts include data for AUSTEDO (deutetrabenazine) tablets, as well as once-daily AUSTEDO XR (deutetrabenazine) extended-release tablets.

Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting

Millions of people are scrambling to navigate the Adderall shortage in a saga closely watched by investors in Teva and other drug stocks. Here's what you should know.

The Byzantine Adderall Shortage Puts Teva And Others In The Hot Seat

PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that a respiratory patient monitoring program using data from Teva's Digihaler System has been implemented within California's Desert Oasis Healthcare (DOHC) system.

Teva's Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System

Ambev

LM Ericsson Telefon

Himax Tech

Nokia

Pitney Bowes

Sirius XM Holdings Inc

Investors looking for a bargain and potential upside have strong buy stocks under $10 to consider. Investors should snap up companies that have value without sacrificing quality or growth.

7 Strong Buy Stocks Under $10 to Snap Up Now

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Barclays Global Healthcare Conference March 14, 2023 10:15 AM ET Company Participants Eli Kalif - EVP and CFO Conference Call Participants Balaji Prasad - Barclays Balaji Prasad Good morning, everyone. My name is Balaji Prasad, I'm the Senior Analyst for the Barclays Specialty Pharmaceuticals coverage.

Teva Pharmaceutical Industries Limited (TEVA) Barclays Global Healthcare Conference (Transcript)

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) and that it is increasing the tender caps as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: 7.

News for Teva Pharmaceutical Stock (TEVA)